Shixue Yang

491 total citations
18 papers, 307 citations indexed

About

Shixue Yang is a scholar working on Molecular Biology, Cancer Research and Genetics. According to data from OpenAlex, Shixue Yang has authored 18 papers receiving a total of 307 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 9 papers in Cancer Research and 4 papers in Genetics. Recurrent topics in Shixue Yang's work include Cancer, Hypoxia, and Metabolism (4 papers), Glioma Diagnosis and Treatment (4 papers) and MicroRNA in disease regulation (3 papers). Shixue Yang is often cited by papers focused on Cancer, Hypoxia, and Metabolism (4 papers), Glioma Diagnosis and Treatment (4 papers) and MicroRNA in disease regulation (3 papers). Shixue Yang collaborates with scholars based in China, United States and Germany. Shixue Yang's co-authors include Xiaoteng Cui, Chunsheng Kang, Qixue Wang, Yanli Tan, Biao Hong, Qi Zhan, Kaikai Yi, Chuan Fang, Jixing Zhao and Can Xu and has published in prestigious journals such as Frontiers in Immunology, Cancer Letters and Theranostics.

In The Last Decade

Shixue Yang

15 papers receiving 307 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Shixue Yang China	9	204	136	70	43	42	18	307
Biao Hong China	11	211 1.0×	150 1.1×	80 1.1×	41 1.0×	35 0.8×	19	312
Jixing Zhao China	12	243 1.2×	167 1.2×	90 1.3×	49 1.1×	30 0.7×	16	371
Amber B. Jones United States	6	133 0.7×	96 0.7×	63 0.9×	71 1.7×	32 0.8×	9	250
Mira Li Canada	8	166 0.8×	64 0.5×	64 0.9×	55 1.3×	23 0.5×	12	309
Fangling Cheng China	9	153 0.8×	96 0.7×	87 1.2×	63 1.5×	21 0.5×	18	339
Wojciech Szopa Poland	5	136 0.7×	118 0.9×	151 2.2×	47 1.1×	57 1.4×	8	339
Do-Hyun Nam South Korea	4	167 0.8×	91 0.7×	95 1.4×	18 0.4×	28 0.7×	5	255
Rosalie Schnoor Netherlands	6	201 1.0×	144 1.1×	97 1.4×	54 1.3×	89 2.1×	8	355
Vaidehi Mahadev United States	4	148 0.7×	81 0.6×	139 2.0×	49 1.1×	46 1.1×	6	300
Yin-sheng Chen China	9	181 0.9×	137 1.0×	119 1.7×	43 1.0×	19 0.5×	11	341

Countries citing papers authored by Shixue Yang

Since Specialization

Citations

This map shows the geographic impact of Shixue Yang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shixue Yang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shixue Yang more than expected).

Fields of papers citing papers by Shixue Yang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shixue Yang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shixue Yang. The network helps show where Shixue Yang may publish in the future.

Co-authorship network of co-authors of Shixue Yang

This figure shows the co-authorship network connecting the top 25 collaborators of Shixue Yang. A scholar is included among the top collaborators of Shixue Yang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shixue Yang. Shixue Yang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Hong, Biao, Shixue Yang, Xing Cui, et al.. (2025). Linagliptin synergizes with cPLA2 inhibition to enhance temozolomide efficacy by interrupting DPP4-mediated EGFR stabilization in glioma. Acta Pharmaceutica Sinica B. 15(7). 3632–3645.

Zhan, Qi, Kaikai Yi, Shixue Yang, et al.. (2025). LPC-engineered liposomes activate transcytosis for paclitaxel brain delivery and potentiation of TTFields/TMZ via TALECT regimen in glioblastoma. Theranostics. 16(5). 2249–2268.

Yuan, Ye, Shixue Yang, Lihong Wang, et al.. (2025). Endothelial cell-derived SDF-1α elicits stemness traits of glioblastoma via dual-regulation of GLI1. Theranostics. 15(18). 9819–9837.

Yang, Eryan, Biao Hong, Yunfei Wang, et al.. (2024). EPIC-0628 abrogates HOTAIR/EZH2 interaction and enhances the temozolomide efficacy via promoting ATF3 expression and inhibiting DNA damage repair in glioblastoma. Cancer Letters. 588. 216812–216812. 10 indexed citations

Gong, Li, Shixue Yang, Junli Huang, & Yongsheng Li. (2024). Modulation of gut microbiota in targeted cancer therapy: insights on the EGFR/VEGF/KRAS pathways. Cancer Biology and Medicine. 21(12). 1–15. 2 indexed citations

Zhao, Jixing, Xiaoteng Cui, Zhan Qi, et al.. (2024). CRISPR-Cas9 library screening combined with an exosome-targeted delivery system addresses tumorigenesis/TMZ resistance in the mesenchymal subtype of glioblastoma. Theranostics. 14(7). 2835–2855. 21 indexed citations

Xiao, Menglin, Xiaoteng Cui, Jixing Zhao, et al.. (2024). Deep‐targeted gene sequencing reveals ARID1A mutation as an important driver of glioblastoma. CNS Neuroscience & Therapeutics. 30(4). e14698–e14698. 6 indexed citations

Yang, Shixue, Qi Zhan, Xiaoteng Cui, et al.. (2024). HIF1α/ATF3 partake in PGK1 K191/K192 succinylation by modulating P4HA1/succinate signaling in glioblastoma. Neuro-Oncology. 26(8). 1405–1420. 24 indexed citations

Cui, Xiaoteng, Jixing Zhao, Guanzhang Li, et al.. (2023). Blockage of EGFR/AKT and mevalonate pathways synergize the antitumor effect of temozolomide by reprogramming energy metabolism in glioblastoma. Cancer Communications. 43(12). 1326–1353. 22 indexed citations

10.

Hong, Biao, Eryan Yang, Xiaoteng Cui, et al.. (2023). EPIC-1042 as a potent PTRF/Cavin1–caveolin-1 interaction inhibitor to induce PARP1 autophagic degradation and suppress temozolomide efflux for glioblastoma. Neuro-Oncology. 26(1). 100–114. 10 indexed citations

11.

Li, Lijie, Qi Zhan, Kaikai Yi, et al.. (2022). Engineering Lipusu with lysophosphatidylcholine for improved tumor cellular uptake and anticancer efficacy. Journal of Materials Chemistry B. 10(11). 1833–1842. 8 indexed citations

12.

Yang, Shixue, Jixing Zhao, Xiaoteng Cui, et al.. (2022). TCA-phospholipid-glycolysis targeted triple therapy effectively suppresses ATP production and tumor growth in glioblastoma. Theranostics. 12(16). 7032–7050. 36 indexed citations

13.

Yi, Kaikai, Xiaoteng Cui, Xing Liu, et al.. (2022). PTRF/Cavin-1 as a Novel RNA-Binding Protein Expedites the NF-κB/PD-L1 Axis by Stabilizing lncRNA NEAT1, Contributing to Tumorigenesis and Immune Evasion in Glioblastoma. Frontiers in Immunology. 12. 802795–802795. 26 indexed citations

14.

Zhao, Jixing, Shixue Yang, Xiaoteng Cui, et al.. (2022). A novel compound EPIC-0412 reverses temozolomide resistance via inhibiting DNA repair/MGMT in glioblastoma. Neuro-Oncology. 25(5). 857–870. 43 indexed citations

15.

Zhan, Qi, Kaikai Yi, Xiaoteng Cui, et al.. (2022). Blood exosomes-based targeted delivery of cPLA2 siRNA and metformin to modulate glioblastoma energy metabolism for tailoring personalized therapy. Neuro-Oncology. 24(11). 1871–1883. 87 indexed citations

16.

Xin, Wenqiang, Shixue Yang, Qifeng Li, & Xinyu Yang. (2021). Endarterectomy versus stenting for the prevention of periprocedural stroke or death in patients with symptomatic or asymptomatic carotid stenosis: a meta-analysis of 10 randomized trials. Annals of Translational Medicine. 9(3). 256–256. 3 indexed citations

17.

Xin, Wenqiang, et al.. (2020). Risk factors involved in the formation of multiple intracranial aneurysms. Clinical Neurology and Neurosurgery. 198. 106172–106172. 2 indexed citations

18.

Wei, Fanchao, Yan Zhao, Wentao Dong, et al.. (2015). Intracranial aneurysm risk factor genes: relationship with intracranial aneurysm risk in a Chinese Han population. Genetics and Molecular Research. 14(2). 6865–6878. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact